Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Biosimilar Interleukins Market Expected to Grow Between 2025 And 2029?
In recent times, the biosimilar interleukins market has seen an explosive growth. The market, which was worth $3.9 billion in 2024, is forecasted to reach a value of $5.41 billion in 2025, at a compound annual growth rate (CAGR) of 39.0%. The significant growth seen in previous years can be linked to a rise in autoimmune diseases, growing knowledge of biosimilar interleukins, increased government backing for biosimilars, expansion of the biosimilar market and a rising demand from patients for biosimilars.
What Growth Rate Is Anticipated for the Biosimilar Interleukins Market in the Coming Years?
The market for biosimilar interleukins is predicted to witness significant expansion in the upcoming years, forecasting to reach a value of $20.79 billion by 2029, with a compounded annual growth rate of 40.0%. The expected upswing during the forecast period can be credited to factors such as a growing patient count, broader healthcare accessibility, a surge in personalized medicine demand, and increased preference for minimally invasive procedures. Major anticipated trends during this timeline include progress in biosimilar technology, targeted immunotherapies, quality checks and manufacturing, and worldwide collaboration.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp
Who Are the Leading Companies in the Biosimilar Interleukins Market?
Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.
What Are the Key Drivers of the Biosimilar Interleukins Market?
The rise in autoimmune diseases like psoriasis and rheumatoid arthritis is projected to significantly impact the interleukin biosimilars market positively in the upcoming years. Autoimmune diseases occur when immune cells are unable to differentiate between healthy cells and potentially harmful antibodies. Biologic drugs, such as anti-interleukin antibodies, have demonstrated immense clinical benefit in controlling these cells and governing their proliferation, activation, and migration. The National Institutes of Health (NIH), a reputable American biomedical research agency, indicated in February 2024 reports that the global incidence and prevalence of autoimmune diseases are projected to grow annually by 19.1% and 12.5%, respectively. Therefore, as autoimmune diseases become more common, the demand for biosimilar interleukins is expected to rise, propelling the market growth.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=3433&type=smp
What Are the Key Market Segments in the Biosimilar Interleukins Industry?
The biosimilar interleukins market covered in this report is segmented –
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes
Subsegments:
1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management
2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment
3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders
4) By IL-5: Asthma Treatment, Eosinophilic Disorders
5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment
What Are the Latest Trends in the Biosimilar Interleukins Market?
Major corporations in the biosimilar interleukins market are creating innovative products like Tofidence (tocilizumab-bavi) to boost their market profitability. Tofidence is a monoclonal antibody that targets interleukin-6 receptors and is used in treating various inflammatory autoimmune disorders. For example, Biogen, an American biotech firm, received FDA approval for Tofidence (tocilizumab-bavi) as the initial biosimilar to reference Genentech’s Actemra (tocilizumab) in September 2023. Tofidence is dispensed through intravenous infusion and has been sanctioned for the treatment of severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report
What Are the Key Regional Markets in the Biosimilar Interleukins Industry?
The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3433
This Report Delivers Insight On:
1. How big is the biosimilar interleukins market, and how is it changing globally?
2. Who are the major companies in the biosimilar interleukins market, and how are they performing?
3. What are the key opportunities and risks in the biosimilar interleukins market right now?
4. Which products or customer segments are growing the most in the biosimilar interleukins market?
5. What factors are helping or slowing down the growth of the biosimilar interleukins market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
